trabectedin
Sign in to saveAlso known as ecteinascidin 743, ET-743, Yondelis®, Ect 743, ET743, Ecteinascidin, Ecteinascidin 743
Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.
Research
1,148 papers- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.The New England journal of medicine · 2024
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.The Lancet. Oncology · 2022
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
- Trabectedin in Cancers: Mechanisms and Clinical Applications.Current pharmaceutical design · 2022
- Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?Drug design, development and therapy · 2024
via PubMed
~9 min read
Encyclopedic overview
11 sectionsContents
- Discovery and production
- Approvals and indications
- Soft tissue sarcoma
- Ovarian cancer and other
- Structure
- Biosynthesis
- Total synthesis
- Mechanism of action
- Society and culture
- Legal status
- References
Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.
The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache.
Excerpted from Wikipedia’s “trabectedin” article, available under the CC BY-SA 4.0 licence.